Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth
复制标题

DOI:
10.1101/2023.03.10.532081
复制
发表时间:
2023-04
期刊:
bioRxiv
影响因子:
--
通讯作者:
S. Kellaway;S. Potluri;P. Keane;H. Blair;P. Chin;A. Ptasinska;Alice Worker;L. Ames;Assunta Adamo;D. Coleman;Naeem Khan;Salam A. Assi;A. Krippner-Heidenreich;M. Raghavan;P. Cockerill;O. Heidenreich;C. Bonifer
S. Kellaway;S. Potluri;P. Keane;H. Blair;P. Chin;A. Ptasinska;Alice Worker;L. Ames;Assunta Adamo;D. Coleman;Naeem Khan;Salam A. Assi;A. Krippner-Heidenreich;M. Raghavan;P. Cockerill;O. Heidenreich;C. Bonifer
中科院分区:
其他
文献类型:
--
作者:
S. Kellaway;S. Potluri;P. Keane;H. Blair;P. Chin;A. Ptasinska;Alice Worker;L. Ames;Assunta Adamo;D. Coleman;Naeem Khan;Salam A. Assi;A. Krippner-Heidenreich;M. Raghavan;P. Cockerill;O. Heidenreich;C. Bonifer

文献摘要

相似文献

急性髓细胞白血病(AML)是由髓细胞生长和分化失调的多种突变引起的。细胞采用不同的基因调控网络特异性的个体突变,维持一个快速增殖的胚细胞群体,致命的后果,如果不治疗的病人。最常见的治疗选择仍然是针对这些细胞的化疗。然而,患者体内有一群静止的白血病干细胞(LSCs),它们可以从静止状态中出现,在治疗后引发复发。允许这些细胞再生的过程尚不清楚。在这里,我们研究了表征良好的t(8;21) AML亚型作为解决这个问题的模型。使用一种新的t(8;21)患者来源的异种移植模型,我们发现t(8;21) LSCs异常激活VEGF和IL-5信号通路。这两种途径都在一个由驱动癌蛋白RUNX1::ETO和AP-1/GATA2轴组成的调控回路中运作,允许LSCs在保持自我更新能力的同时重新进入细胞周期。
Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly proliferating blast cell population with fatal consequences for the patient if not treated. The most common treatment option is still chemotherapy which targets such cells. However, patients harbour a population of quiescent leukemic stem cells (LSCs) which can emerge from quiescence to trigger relapse after therapy. The processes that allow such cells to re- grow remain unknown. Here, we examined the well characterised t(8;21) AML sub-type as a model to address this question. Using a novel t(8;21) patient-derived xenograft model, we show that t(8;21) LSCs aberrantly activate the VEGF and IL-5 signalling pathways. Both pathways operate within a regulatory circuit consisting of the driver oncoprotein RUNX1::ETO and an AP-1/GATA2 axis allowing LSCs to re-enter the cell cycle while preserving self-renewal capacity.